Pneumococcal vaccination (PV) rates are low in patients with chronic kidney disease (CKD) stages 4,5 and nephrotic syndrome, despite of higher incidence of pneumococcal pneumonia and increased mortality and cardiovascular complications in these patients compared to patients without CKD 1,2. We implemented quality improvement (QI) project involving a best practice alert (BPA) implementation in CKD clinics to improve PV rates amongst these high risk patients over a 2-year period.This initiative was approved by Institutional Quality Review Committee (QIIRB2097);projects approved as QI initiatives did not require informed patient consent per institutional policy.
Category: American Journal of Kidney Diseases
American Journal of Kidney Diseases
Long-term Health Care Utilization and Associated Costs After Dialysis-Treated Acute Kidney Injury in Children
Acute kidney injury (AKI) is common among hospitalized children and is associated with increased hospital length of stay and costs. However, there are limited data on post-discharge healthcare utilization after AKI hospitalization. Our objectives were to evaluate healthcare utilization and physician follow-up patterns after pediatric dialysis-treated AKI.
While interest in peritoneal dialysis (PD) is growing in many parts of the world given its patient-centric approach and favorable cost profile, peritonitis remains a major problem. Some risk factors have been identified, but many of these are not modifiable. One that deserves closer scrutiny is hypokalemia, which has been associated with an increased risk for peritonitis.1-3 The impact of treatment of hypokalemia on peritonitis risk has not been previously closely examined.
Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration
In the past decade, advances in the validation of surrogate end points for chronic kidney disease (CKD) progression have heightened interest in evaluating therapies in early CKD. In December 2020, the National Kidney Foundation sponsored a scientific workshop in collaboration with the US Food and Drug Administration (FDA) to explore patient, provider, and payor perceptions of the value of treating early CKD. The workshop reviewed challenges for trials in early CKD, including trial designs, identification of high-risk populations, and cost-benefit and safety considerations.
Adult-Onset Focal Segmental Glomerulosclerosis With Steroid-Dependent Nephrotic Syndrome Caused by a Novel TBC1D8B Variant: A Case Report and Literature Review
Focal and segmental glomerulosclerosis (FSGS) is a histological lesion due to many causes including rare mutations of podocyte related genes. Recently, it has been found that TBC1D8B mutations can lead to early-onset FSGS and steroid-resistant nephrotic syndrome (NS) by influencing endocytic and recycling of nephrin. Here, we report a 19-year-old Chinese patient with NS and normal renal function. He had a complete remission of NS after full-dose prednisone and cyclosporine treatment. Unfortunately, a relapse of NS occurred during prednisone tapering.